CORXEL

CORXEL develops world-class treatments for critical and life-threatening diseases. Founded with investment from RTW Investments, CORXEL is committed to serving Chinese patients suffering from severe and life-threatening conditions by providing innovative scientific therapies and drugs to address unmet clinical needs. Currently, CORXEL’s lead program is a novel oral small-molecule cardiac myosin inhibitor (CK-274) licensed from Cytokinetics for the treatment of hypertrophic cardiomyopathy.